The strategic priorities reflected in Deckers DECK results Deckers Beats Estimates by 18 Percent Vertex Pharmaceuticals VRTX Partnered CRISPR Therapeutics Upcoming Clinical Catalysts Present Symbiotic Upside Opportunity JDcom Inc JD Positioned to Benefit from Broad Global Retail Sector Momentum Amid Robust March Sales Growth Is KimberlyClark Corporation KMB stock still attractive Q4 2025 Profit Exceeds Views